{"id":71409,"date":"2026-07-30T20:52:05","date_gmt":"2026-07-30T12:52:05","guid":{"rendered":"https:\/\/flcube.com\/?p=71409"},"modified":"2026-07-30T20:52:06","modified_gmt":"2026-07-30T12:52:06","slug":"buchang-pharmaceuticals-withdraws-efperepoetin-alfa-registration-application-for-ckd-anemia-due-to-dossier-enhancement-requirements","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71409","title":{"rendered":"Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shandong Buchang Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/603858:SHA\">SHA: 603858<\/a>) announced the <strong>voluntary withdrawal of its drug registration application for efperepoetin alfa<\/strong>, a <strong>recombinant fusion protein<\/strong> comprising <strong>human erythropoietin (EPO) and the Fc fragment of human immunoglobulin G2 (IgG2)<\/strong>, indicated for the treatment of <strong>anemia due to chronic kidney disease (CKD) in adult dialysis patients receiving erythropoietin therapy<\/strong>. The company cited the <strong>need for further improvement of application dossiers<\/strong> as the primary reason for withdrawal, noting that <strong>no similar product has been approved for marketing in China<\/strong> to date.<\/p>\n\n\n\n<h2 id=\"h-regulatory-development\" class=\"wp-block-heading\">Regulatory Development<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Efperepoetin alfa \u2013 recombinant EPO-Fc fusion protein<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Anemia due to chronic kidney disease (CKD) in adult dialysis patients on erythropoietin therapy<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>Voluntary withdrawal of drug registration application<\/td><\/tr><tr><td><strong>Reason for Withdrawal<\/strong><\/td><td>Need for further improvement of application dossiers<\/td><\/tr><tr><td><strong>Market Status<\/strong><\/td><td>No similar EPO-Fc fusion product approved in China<\/td><\/tr><tr><td><strong>Technology Platform<\/strong><\/td><td>Recombinant fusion protein with extended half-life properties<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-therapeutic-rationale\" class=\"wp-block-heading\">Product Profile &amp; Therapeutic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecular Structure:<\/strong> <strong>Recombinant fusion protein<\/strong> combining <strong>human erythropoietin (EPO)<\/strong> with <strong>Fc fragment of human IgG2<\/strong>, designed to extend serum half-life through neonatal Fc receptor (FcRn) recycling mechanism<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Potential for <strong>less frequent dosing<\/strong> compared to conventional erythropoiesis-stimulating agents (ESAs), improving patient convenience and compliance in chronic dialysis settings<\/li>\n\n\n\n<li><strong>Target Population:<\/strong> <strong>Adult CKD patients on dialysis<\/strong> currently receiving erythropoietin therapy, representing a significant portion of China&#8217;s estimated <strong>300,000+ dialysis patients<\/strong><\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> While <strong>EPO-Fc fusion proteins<\/strong> like <strong>efapegotin alfa<\/strong> (marketed as Retacrit\u00ae in some regions) exist globally, <strong>China lacks approved products<\/strong> in this extended-half-life ESA category<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-strategic-implications\" class=\"wp-block-heading\">Market Context &amp; Strategic Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>Chinese anemia management market in CKD<\/strong> represents a substantial commercial opportunity, with <strong>erythropoiesis-stimulating agents (ESAs)<\/strong> generating annual sales exceeding <strong>RMB 2 billion<\/strong>. Current treatment options primarily consist of <strong>short-acting recombinant human EPO<\/strong> requiring <strong>multiple weekly injections<\/strong>, creating significant burden for dialysis patients who already undergo frequent clinic visits.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Extended-half-life ESAs<\/strong> have demonstrated <strong>superior pharmacokinetic profiles<\/strong> and <strong>reduced dosing frequency<\/strong> in international markets, but regulatory approval in China has been limited by <strong>stringent dossier requirements<\/strong> and <strong>comprehensive clinical data expectations<\/strong> from the NMPA.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Key strategic considerations for Buchang:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulatory Strategy:<\/strong> Withdrawal suggests <strong>incomplete or insufficient clinical\/non-clinical data packages<\/strong> rather than safety or efficacy concerns<\/li>\n\n\n\n<li><strong>Development Timeline:<\/strong> Re-submission likely requires <strong>additional studies or enhanced documentation<\/strong>, potentially delaying market entry by <strong>12-24 months<\/strong><\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> First-mover advantage remains available given <strong>absence of approved competitors<\/strong> in China&#8217;s EPO-Fc segment<\/li>\n\n\n\n<li><strong>Portfolio Impact:<\/strong> Represents setback in Buchang&#8217;s <strong>biologics diversification strategy<\/strong> beyond traditional Chinese medicine products<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-next-steps-amp-outlook\" class=\"wp-block-heading\">Next Steps &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dossier Enhancement:<\/strong> Comprehensive review and strengthening of <strong>clinical, non-clinical, and CMC (Chemistry, Manufacturing, Controls) documentation<\/strong><\/li>\n\n\n\n<li><strong>Regulatory Resubmission:<\/strong> Target re-filing once dossier improvements are completed, potentially under <strong>enhanced communication protocols<\/strong> with NMPA<\/li>\n\n\n\n<li><strong>Clinical Development:<\/strong> Possible requirement for <strong>additional comparative studies<\/strong> or <strong>pharmacokinetic\/pharmacodynamic data<\/strong> to support extended dosing claims<\/li>\n\n\n\n<li><strong>Manufacturing Validation:<\/strong> Enhanced <strong>process validation and quality control documentation<\/strong> to meet NMPA biologics standards<\/li>\n\n\n\n<li><strong>Market Preparation:<\/strong> Continued engagement with <strong>key opinion leaders and dialysis centers<\/strong> to maintain awareness of product potential<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-industry-context\" class=\"wp-block-heading\">Industry Context<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This withdrawal reflects the <strong>increasingly stringent regulatory environment<\/strong> for biologics in China, where the NMPA has implemented <strong>comprehensive review standards<\/strong> aligned with international guidelines. Companies developing <strong>biosimilars and novel biologics<\/strong> face heightened expectations for <strong>robust clinical data, comprehensive safety profiles, and manufacturing excellence<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>extended-half-life ESA market<\/strong> remains attractive despite regulatory challenges, with <strong>global products demonstrating 20-30% market share<\/strong> in developed markets and <strong>premium pricing<\/strong> justified by improved patient outcomes and reduced healthcare resource utilization.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory resubmission timelines, development plans, and market opportunities. Actual results may differ due to risks including regulatory requirements, competitive developments, clinical data requirements, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/603858_20260730_508S.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 603858_20260730_508S.\"><\/object><a id=\"wp-block-file--media-2f7d6dbb-6537-440c-8e8e-41ea74e637f8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/603858_20260730_508S.pdf\">603858_20260730_508S<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/603858_20260730_508S.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2f7d6dbb-6537-440c-8e8e-41ea74e637f8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced the voluntary withdrawal of its drug registration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[280,1103],"class_list":["post-71409","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-buchang-pharmaceuticals","tag-sha-603858"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced the voluntary withdrawal of its drug registration application for efperepoetin alfa, a recombinant fusion protein comprising human erythropoietin (EPO) and the Fc fragment of human immunoglobulin G2 (IgG2), indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients receiving erythropoietin therapy. The company cited the need for further improvement of application dossiers as the primary reason for withdrawal, noting that no similar product has been approved for marketing in China to date.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71409\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements\" \/>\n<meta property=\"og:description\" content=\"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced the voluntary withdrawal of its drug registration application for efperepoetin alfa, a recombinant fusion protein comprising human erythropoietin (EPO) and the Fc fragment of human immunoglobulin G2 (IgG2), indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients receiving erythropoietin therapy. The company cited the need for further improvement of application dossiers as the primary reason for withdrawal, noting that no similar product has been approved for marketing in China to date.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71409\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-30T12:52:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-30T12:52:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71409#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71409\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements\",\"datePublished\":\"2026-07-30T12:52:05+00:00\",\"dateModified\":\"2026-07-30T12:52:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71409\"},\"wordCount\":629,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Buchang Pharmaceuticals\",\"SHA: 603858\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71409#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71409\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71409\",\"name\":\"Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-30T12:52:05+00:00\",\"dateModified\":\"2026-07-30T12:52:06+00:00\",\"description\":\"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced the voluntary withdrawal of its drug registration application for efperepoetin alfa, a recombinant fusion protein comprising human erythropoietin (EPO) and the Fc fragment of human immunoglobulin G2 (IgG2), indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients receiving erythropoietin therapy. The company cited the need for further improvement of application dossiers as the primary reason for withdrawal, noting that no similar product has been approved for marketing in China to date.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71409#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71409\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71409#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements - Insight, China&#039;s Pharmaceutical Industry","description":"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced the voluntary withdrawal of its drug registration application for efperepoetin alfa, a recombinant fusion protein comprising human erythropoietin (EPO) and the Fc fragment of human immunoglobulin G2 (IgG2), indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients receiving erythropoietin therapy. The company cited the need for further improvement of application dossiers as the primary reason for withdrawal, noting that no similar product has been approved for marketing in China to date.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71409","og_locale":"en_US","og_type":"article","og_title":"Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements","og_description":"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced the voluntary withdrawal of its drug registration application for efperepoetin alfa, a recombinant fusion protein comprising human erythropoietin (EPO) and the Fc fragment of human immunoglobulin G2 (IgG2), indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients receiving erythropoietin therapy. The company cited the need for further improvement of application dossiers as the primary reason for withdrawal, noting that no similar product has been approved for marketing in China to date.","og_url":"https:\/\/flcube.com\/?p=71409","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-30T12:52:05+00:00","article_modified_time":"2026-07-30T12:52:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71409#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71409"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements","datePublished":"2026-07-30T12:52:05+00:00","dateModified":"2026-07-30T12:52:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71409"},"wordCount":629,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Buchang Pharmaceuticals","SHA: 603858"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71409#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71409","url":"https:\/\/flcube.com\/?p=71409","name":"Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-30T12:52:05+00:00","dateModified":"2026-07-30T12:52:06+00:00","description":"Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced the voluntary withdrawal of its drug registration application for efperepoetin alfa, a recombinant fusion protein comprising human erythropoietin (EPO) and the Fc fragment of human immunoglobulin G2 (IgG2), indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients receiving erythropoietin therapy. The company cited the need for further improvement of application dossiers as the primary reason for withdrawal, noting that no similar product has been approved for marketing in China to date.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71409#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71409"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71409#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71409"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71409\/revisions"}],"predecessor-version":[{"id":71411,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71409\/revisions\/71411"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}